REGULATORY

• MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
  July 4, 2023

• MHLW Panel OKs 282 More Health Damage Claims for COVID Vaccines
  July 4, 2023

• Hiroyuki Uchiyama Tapped as Assistant Vice Minister for Pharma Promotion
  July 3, 2023

• LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
  July 3, 2023

• Average Annual Pay for PMDA Staffers at 7.71 Million Yen in FY2022
  July 3, 2023

• MHLW Reports 3 New Cases of Inadvertent Use of Xocova in Pregnant Women
  July 3, 2023

• Study Group of Lawmakers, Industry Urges Earlier Launch of Genome Analysis Project Organ
  July 3, 2023

• MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
  June 30, 2023

• Japan to Revise Generic Use Target to Value-Based Figure
  June 30, 2023

• MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
  June 29, 2023

• Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
  June 29, 2023

• PMDA Reviewing Anaphylaxis Risk for Xocova
  June 29, 2023

• MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
  June 28, 2023

• After Years of Debates, Wholesalers’ Negative Primary Margins Remain a Problem
  June 28, 2023

• SCARDA, CEPI Ink Pact to Beef Up Collab for Vaccine Development
  June 28, 2023

• Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
  June 27, 2023

• Ryukaikon Calls for Correcting Excessive Yakkasa by Revising Distribution Guidelines
  June 27, 2023

• Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
  June 27, 2023

• Japan Reports World’s 1st Death from Oz Virus
  June 26, 2023

• PMDA Reviewing Safety Risks for 10 Statin Drugs, Tirzepatide
  June 26, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 78
• 79
• 80
• 81
• 82
• 83
• 84
• 85
• 86
• …
• Next ›
• 最終 »